Continuous arteriovenous hemofiltration in acute renal failure

Am J Kidney Dis. 1985 Dec;6(6):373-86. doi: 10.1016/s0272-6386(85)80099-8.

Abstract

This extensive review describes the settings for continuous arteriovenous hemofiltration (CAVH) and attempts to compare it to traditional dialysis therapies for acute renal failure. In addition hemodynamic stability, membrane biocompatibility, nutrition, fluid and solute removal, operational characteristics, anticoagulation, replacement solutions, drug removal, complications, and trouble shooting during CAVH are all discussed in detail. The cost of CAVH v dialysis is equal. CAVH is probably the renal replacement therapy of choice for hemodynamically unstable patients with acute renal failure and contraindications to peritoneal dialysis.

Publication types

  • Review

MeSH terms

  • Acute Kidney Injury / physiopathology
  • Acute Kidney Injury / therapy*
  • Anti-Bacterial Agents / metabolism
  • Anticoagulants / administration & dosage
  • Biocompatible Materials
  • Blood*
  • Fluid Therapy
  • Hemodynamics
  • Humans
  • Nutritional Physiological Phenomena
  • Pharmaceutical Preparations / blood
  • Renal Dialysis / adverse effects
  • Ultrafiltration* / instrumentation
  • Ultrafiltration* / methods

Substances

  • Anti-Bacterial Agents
  • Anticoagulants
  • Biocompatible Materials
  • Pharmaceutical Preparations